This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LATS1 · Western blot design guide
LATS1 Western Blot Planning Guide
Plan a LATS1 Western blot around the catalog-observed 126.9 kDa band, image-backed A01051-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
LATS1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 126.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Gallbladder | |
| Negative control | Spleen |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 126.9 kDa |
| ⓘ | Localization | Cytoplasm, cytoskeleton, microtubule organizing center, centrosome / Cytoplasm, cytoskeleton, spindle |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated LATS1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Wet/tank, extended transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A01051-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected LATS1 Western Blot Band Size?
Use the product-observed 126.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 126.9 kDa | Matches the authoritative product WB observation. |
| 126.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected LATS1 appearancePlan around 126.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 126.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 126.9 kDa from UniProt O95835; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A01051-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 126.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing LATS1 band
A01051-2 · LATS1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for LATS1 Western blot
🧪Use Gallbladder as the first positive-control candidate and Spleen as the HPA Not detected negative candidate.
Positive control: Gallbladder (High)
Negative control: Spleen (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for LATS1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Gallbladder | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Spleen | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced LATS1 Western Blot Tips
Deeper troubleshooting and optimisation questions for LATS1, answered from its protein features.
Which band should guide the blot?
Use 126.9 kDa, the observation attached to the authoritative A01051-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 126.9 kDa expectation.
Which positive control should I start with?
Start with Gallbladder, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Spleen as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for LATS1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01051-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
LATS1 Western Blot Reagents
Human/Mouse/Rat-reactive LATS1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-LATS1 Antibody Picoband®
Cat # A01051-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt O95835
- Human Protein Atlas — LATS1
- A01051-2 product record
- PMC12927312 — Cytosolic nucleic acid sensing triggers type I interferon activation via the Hippo kinase LATS1 (The Journal of biological chemistry, 2026)
- PMC3404884 — LATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progression (The Journal of cell biology, 2012)
- PMC13172046 — USP25 aggravates liver cancer development and impairs chemosensitivity by limiting LATS1 activation (EMBO reports, 2026)
